以下演讲人将于本届 ChinaBio® 创业投资论坛做精彩演讲。
Greg B. Scott - President and Founder, ChinaBio® LLC
Greg Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded ChinaBio® Accelerator to help fund and mentor early stage life science companies in China. He is also the Founding Principal of ChinaBio® Consulting which assists U.S. and China life science companies and investors leverage the opportunities available in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 30 biotechnology and medical device companies since 2005, and executive editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and founded and sold three high-tech firms. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.
Mikael Oerum - Co-Founder and General Partner, Ventac Partners
Mikael Oerum is co-founder and General Partner of Ventac Partners (www.ventac-partners.com) since 2002. He holds more than 30 years of executive experience in the biotechnology and finance sectors with proven track record in identifying business opportunities, developing and executing strategic business plans, fund raising, and international deal making. Since 2005, Mikael Oerum also serves as President & CEO of Avexxin (www.avexxin.com). Mikael Oerum is serving as Chairman and/or Board Member of several biotech and other companies. He is Vice Chairman of Medicon Valley Academy (www.mva.org), member of the Council of the Danish Technical University (www.dtu.dk) and of the advisory board of the Institute of Micro- and Nanotechnology (www.mic.dtu.dk). He is advisor to several universities on matters of commercialization of life science research and frequent speaker and moderator at conferences. Prior to joining Ventac Partners, Mikael Oerum held the position as CEO of Exiqon A/S (www.exiqon.com), listed on Copenhagen stock exchange. Furthermore, he is co-founder of Santaris Pharma, A/S (www.santaris.com), and Avexxin AS (www.avexxin.com). Within the life science sector he has over time served on several government committees and has participated in international projects focusing on healthcare, industrial growth and biotech initiatives. Until 1995, Mikael Oerum held several executive positions across the financial and electronic engineering sectors responsible for large organizational, IT and other technology departments and projects.
George Chang, MBA – Morningside
Mr. Chang joined Morningside in 1991. Mr. Chang started his professional career in a major international accounting firm and has over eight years experience in public accounting in Hong Kong and Toronto. Prior to joining Morningside, Mr. Chang held senior financial positions in several international manufacturing and trading companies. Mr. Chang received his M.B.A. degree from the University of Wisconsin at Madison and is a member of the American Institute of Certified Public Accountants, Canadian Institute of Chartered Accountants and Hong Kong Institute of Certified Public Accountants. He sits on the board of several private companies in Asia and North America. Mr. Chang formerly served as a board member of the publicly-traded companies Sohu.com and Media Partners International Holdings Inc.
Tien-yo Chao – Partner, Morrison & Foerster
Tien-yo Chao is a partner of Morrison & Foerster at its Hong Kong office. He has practised in Hong Kong since 1983, focusing on M&A, securities offerings, private equity and other corporate transactions and regulatory compliance, both in Hong Kong and in the Greater China region. He joined Slaughter and May in 1986 and became a partner of the firm in 1990. In 1994, Mr. Chao co-founded Chao and Chung, a Hong Kong firm focused on M&A, corporate finance, private equity and regulatory compliance. He joined Morrison & Foerster in 2003. Mr. Chao has extensive, in-depth knowledge of the capital markets and corporate community in Hong Kong and the Greater China region. Mr. Chao has represented over 30 companies in their listings in Hong Kong and also advised some 15 PRC companies in connection with the listing of their H shares or the offering of their B shares. Mr. Chao is a native of Hong Kong and holds a B.A. degree from the University of Hong Kong, an M.A. degree from the University of Keele and a B. Ling degree from the University of Manchester in the U.K. He qualified as a solicitor in England & Wales in 1983 following training in London, and in Hong Kong in 1984.
Helen Chen – Partner and Head of China Life Sciences L.E.K. Consulting
Ms. Helen Chen is a partner at L.E.K. Consulting based in Shanghai and head of L.E.K.’s China life sciences practice. She has 20 years of life science industry and consulting experience in United States and Asia, and has been practicing in China since 2000. Helen’s practice advises life sciences companies in all stages of growth, and financial investors in the commercial opportunities in the China life science sector. Helen was previously associate director of finance at Genentech in San Francisco, California, and held sales planning roles at Abbott Laboratories in North Chicago, Illinois. Helen has an honors BA from Harvard University in applied mathematics and attended the Kellogg Graduate School of Management at Northwestern University. She was a member of Board of Directors for U.S. Pharmaceutical Management Sciences Association (PMSA) from 1995 to 1997, and was honored by Who’s Who Among American Women from 1993 to 1995.
Vasco Cheung – CEO, Cmedtec Limited
Professor Cheung received his training in Chinese medicine at the inaugural class of the Hong Kong University School of Chinese Medicine. His main area of interest is the use of natural herbs and plant extracts to cure chronic diseases and to maintain good health. Over the last 10 years Professor Cheung has traveled to almost every province in China to research and to source the best quality herbs and extracts. He continues a rigorous research program to this day. Professor Cheung is the President of the Ginkgo Applied Research Institute and was Technical Director of the International Association of Chinese Medicine Technology. Professor Cheung established CmedTec in 2003 to develop high technology plant extracts. Today, CmedTec is known for its expertise in Ginkgo and its proprietary low temperature extraction technology.
Louis Choy, MD, MBA – Managing Director, Spring Capital Asia
Dr. Based in Hong Kong, Dr. Louis Choy has 11 years of experience in private equity and healthcare investment, 5 years in business and healthcare strategy consulting and 3 years as a Medical Officer. Louis commenced his private equity career in Transpac Capital, which had USD 820 million under management, in 1997-2000. He led, closed and managed number of PRC expansion stage investments such as Neo-Neon (HKSE:1868.HK, 2006). Prior to Transpac, Dr. Choy worked as the Manager and Head of Strategy Group in Accenture for five years. Before Accenture, he worked as a medical officer in Royal Prince Alfred Hospital in Sydney, Australia. Prior to joining Spring Capital in September 2008, he spent four years managing his family investment office and invested in a number of first round healthcare transactions. Between 2002 to 2004, he was the CEO of Biocentury Holdings (HK), a life science company focused on antibody based therapy. Louis is a registered medical doctor in Australia, U.K. and Hong Kong. He obtained a Bachelor of Medicine and a Bachelor of Surgery from the University of Sydney in 1987, an MBA from the University of New South Wales in 1991, and earned a CFA in 2002. He is fluent in Mandarin, English and Cantonese.
Alex Fowkes, JD – Head of R&D Business Development, Asia, Pfizer (China)
Alex Fowkes obtained undergraduate degrees in science and law in Australia before joining a private practice law firm in 1994. In 1998 Alex joined Pfizer’s operations in the United Kingdom to provide legal support to its European research and development activities. In 2003 Alex moved to the Pfizer Research and Development Division (PGRD) headquarters in New London, Connecticut to lead the global legal support for PGRD’s world-wide technology transfer activities. At the end of 2006 Alex was appointed to lead PGRD’s Strategic Alliance operations in Asia and relocated to Pfizer’s Research Office in Shanghai.
Jennifer Hu, PhD – Director of Licensing & External Research, Merck & Co., USA
Dr. Jing-Shan (Jennifer) Hu is Director of Licensing & External Research (Mailand China, Hong Kong, & Taiwan) with Merck & Co, USA. She is responsible for identifying and developing new product and technology opportunities in Mainland China, Hong Kong, and Taiwan for Merck in the area of partnership, licensing-in, and acquisition. Prior to joining Merck, Jing-Shan spent three years at Roche Palo Alto as Research Leader, heading Functional Biology applying and developing new technologies towards assessment of drug targets and new compounds, following a role as Palo Alto Leader of Toxicogenomics. Prior to that, Jing-Shan worked at Affymetrix in various capacities, including establishing and managing programs with both pharmaceutical and academic partners to demonstrate the application of Affymetrix GeneChip technology in Toxicology/Pharmacogenomics studies. Jing-Shan started her career at Human Genome Sciences, Inc. as a scientist and later as Project Leader of its VEGF-2 Protein Therapeutics Program. Jing-Shan did her post-doctoral research at Harvard Medical School and Massachusetts General Hospital. She earned her Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center and her bachelor's degree from Peking University in Beijing. Jing-Shan has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications.
Stephen Lam, PhD, MBA – Senior Manager, Life Science/ Biotech, Marketing and Admission, HKSTP
Stephen Lam, PhD, MBA joined the Hong Kong Science and Technology Parks Corporation (HKSTP) in November 2006 and is currently a Senior Manager, with the responsibility to develop the Life Sciences and Biotechnology cluster. He brings to the organization over two decades of research, management, and business development experience in the biotechnology industry. Prior to joining HKSTP, Dr. Lam served roles of increasing impact at several multi-national corporations including CIBA-Geigy, Novartis, Syngenta, and Pioneer (a DuPont Company). He also served as founder and Chief Operating Officer of Aryzun Pharmaceuticals, an early-stage drug deve lopment company focused on infectious diseases and oncology. He earned his B.A. at the University of Oregon, his MBA at Duke University, and his Ph.D. at the University of Utah. Dr. Lam is an inventor on 16 issued US patents and authored over two dozen scientific publications.
Nisa Leung, MBA – Partner, Qiming Ventures Partners
Nisa Leung is a Partner of Qiming Ventures specializing in health care investments. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including most recently a founding investment into Novamed Pharmaceuticals Inc (Shanghai), a specialty pharmaceutical company focused on oncology and CNS. Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. Nisa Leung received her MBA from Stanford Graduate School of Business.
Shawn Leung, PhD – Founder and CEO, SinoMab
Dr. Shawn Leung is the scientific founder and CEO of SinoMab. He has had over 20 years of experience in the biotechnology industry and is proficient in the field of therapeutic antibody development. Prior to founding SinoMab, Dr. Leung had served as the Managing Director of the Hong Kong Institute of Biotechnology, and as the Executive Director, Biology Research, of Immunomedics, Inc., of New Jersey, USA. Dr. Leung is an inventor on over 20 patents and the author of more than 70 publications (Nature, Journal of Immunology, Nucleic Acid Research, Cancer Research, Clinical Cancer Research, etc.). His works and contributions in the field of therapeutic antibodies are highly regarded in China, and he is amongst the first non-residents in China obtaining approval as the Project Leader in the 863 program for the development of novel antibody based therapy for liver cancer. Dr. Leung received his D.Phil. in Molecular Biology from Oxford University and was a Howard-Hughes Medical Research fellow at Yale University. Dr. Leung holds various adjunct positions in different academic institutions, including the Biochemistry Department of CUHK, the Third Military Medical University in Chongqing, and the Fourth Military Medical University in Xian.
QY Ma, PhD – CEO, Time Medical Ltd.
Dr. QY Ma has over 20 years of R&D, managerial, and operational experience in North America. He was an Associate Professor at the Columbia University, Harvard Medical School as well as deputy director of JC MRI Engineering center at the University of Hong Kong. He has published over 160 papers, obtained 8 patents and the National Science Foundation Career Award. Dr. Ma’s expertise includes microelectronics, superconductivity, RF circuits, MRI, biomedical devices, technology transfer, and hi-tech start-ups. He has served as a consultant to IBM, General Electric, TRW, Du Pont as well as other leading electronic companies. Dr. Ma has been a co-founder of Semiconductor Manufacture International Corp. (NYSE: SMI) and serves as a board member to several Chinese hi-tech companies including ComTech (NASDQ: COGO) and Benda Pham (NASDAQ: BPMA). Dr. Ma has been an advisor to the Ministry of Information Industry of China, Beijing and Guangzhou governments, as well as to the hi-tech parks in Shanghai, Jinan and Hainan. He was the president of Chinese American Science and Technology Association and is currently the president of Chinese American Innovation and Development Association. Dr. Ma received his Ph.D. from Columbia University, and is a graduate of Stanford Executive Program (SEP) of Stanford Business School.
Don Qiu, PhD, MBA – Principal, ChinaBio® LLC
Dr. Don (Dongxu) Qiu leads ChinaBio's consulting and research activities in China. Don brings extensive management experience in the biotech industry, including research, product development, business development, operations, technology transfer, and venture capital. Dr. Qiu was previously an independent consultant to China biotechnology companies including Wex Pharmaceutical, Nanning Maple Leaf Pharmaceutical, and Beijing Joinn Pharmaceutical, the largest CRO in China. Previously, he was with MDS Capital, where he helped raise a $30M fund and participated in venture investment and technology transfer transactions. Don previously spent nine years in senior management positions with a number of biotechs, taking two compounds to the clinic. He holds a PhD in Medicinal Chemistry from Peking University and an MBA from the Richard Ivey School of Business, the University of Western Ontario.
Yi Shi, PhD – Managing Director, Lilly Asian Ventures
Dr. Yi Shi joined Lilly Asian Ventures in 2007 as a Managing Director based in Shanghai, China. Prior to the current assignment, he worked in various roles with increasing responsibility over six years at Eli Lilly and Company. His experience includes leading the development of a comprehensive investment strategy for China as well as negotiating multiple biotechnology and pre-clinical deals world-wide. Dr. Shi was also instrumental in the founding of InnoCentive, Inc., a Lilly Ventures portfolio company, where he managed scientific operations as well as its expansion into China. Before joining Lilly, Dr. Shi was the Chief Sales and Marketing Officer of NetBig.com, an internet start-up, where he successfully grew the company to become the number one education and technology portal in China. He began his career as a management consultant with Ernst & Young in the Life Science Practice Group and specialized in sales and marketing strategy. Dr. Shi received a PhD in Biochemistry and a Master of Business Administration degree, both from Duke University. He also earned a Bachelor of Science in Biology from the University of Science and Technology of China.
Bing Su, PhD – Vice President R&D, Co-founder, Kunming Biomed International
Dr. Bing Su is the co-founder and vice president of Kunming Biomed International (KBI), one of the leading preclinical CROs in China. He also serves as a principal investigator and deputy director in Kunming Primate Research Center of the Chinese Academy of Sciences (KPRC, CAS). He leads the efforts of developing CNS and metabolic disease models using nonhuman primates at KBI and KPRC, CAS. He is an expert on human genetics. He serves as the editorial boards of multiple scientific journals in China and USA. He attended Wuhan University (China), University of Texas and University of Cincinnati (USA), where he studied and conducted research on cell biology, primatology and human genetics.
E. Anthony Tan – CEO, HKSTP
Mr. Anthony Tan brings nearly 33 years of experience managing and building large organisations in Asia Pacific and globally for DuPont, covering product lines from chemicals to synthetic fabric and fibers like Tyvek® and Lycra®. Mr. Tan began his career with DuPont in the US where he worked in research/development and production. He was also involved in the development of new products/businesses in the areas of Electronic Imaging and Medical Products. He moved back to Asia in the mid 80’s where he was one of the pioneering members in establishing DuPont’s China organizations and businesses since the mid 80’s. His efforts were instrumental in the many DuPont investments in Agrichemicals, Fibers and Polyester film production facilities in Shanghai, Beijing and Pearl River Delta. He joined the public sector in 2006 as the Corporate Services Director of Airport Authority Hong Kong, responsible for Board-related matters, legal and secretarial, human resources, administration and management process improvements.
Melvin Toh, MD – Vice President, Pharmaceutical Development, CK Life Sciences Int’l., (Holdings) Inc.
Dr. Melvin Toh is Vice President, Pharmaceutical Development at CK Life Sciences, with oversight of preclinical development, clinical development, regulatory affairs and clinical quality assurance. He is also actively involved in pharmaceutical business development activities, including identification of partnering opportunities, participation in due diligence, partner negotiations and relationship management. Dr. Toh holds a medical degree from the National University of Singapore and an MSc degree from the University of London, and has almost 20 years of experience in clinical medicine and pharmaceutical R&D. He has held management and scientific leadership positions in Asia and the US. Prior to joining CK Life Sciences in 2008, he was Director in Oncology Development, Pfizer Global R&D, based in the US, where he headed a team of scientists working on the clinical development of new cancer drugs. He was previously the Head and Medical Director of the Pfizer Clinical Research Unit at the Singapore General Hospital, Pfizer’s only early phase clinical research unit in Asia.
Jinyue Wang – China Representative, DSM Venturing
Mr. Wang is currently the Representative of DSM Venturing in China. DSM Venturing is the corporate venture fund (270 Million Euro under management with investment focus at life science and material science sectors) that reports to the DSM Board. Jinyue was the founder of DSM Venture in China in 2007, and he is currently leading the organization as China Representative. Prior to his current role, Mr. Wang worked at DSM (China) Ltd. and was responsible for Strategic Projects (M&A) and Competitive Intelligence from 2003, and was a key contributor to DSM’s corporate and business strategy and the key driver from China for implementation and execution (i.e. M&A). Previously, he was with Roche (China) Ltd. as Business Development Manager and External Affairs Manager from 2000, with responsibility from investment projects, Business Intelligence, regulatory affairs, governmental and public affairs. He has also served as the head of Division of International Cooperation, CCPIE, State Food and Drug Administration (SFDA) from 1998, and as a key member in the Division of Economic Cooperation, Department of International Cooperation, State Pharmaceutical Administration of China (SPAC) from 1996. Mr. Wang obtained his BS from Shenyang Pharmaceutical University, graduated as a Bachelor of Pharmaceutical Engineering, and his MS in biotechnology from Shenyang Pharmaceutical University. He is also a candidate for PhD at law from 2005 at Jilin University.
Stella Xu, PhD – Global Licensing Director, Roche Global Pharma Partnering
Dr. Stella Xu is the Global Licensing Director with Roche Global Pharma Partnering. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management with Asian partners. Prior to her current position, Stella had held multiple global positions in Roche Pharma Partnering and led more than 30 product-focused due diligence projects and alliances such as Toyama, Japan Tobacco, and Maxygen. Stella joined Roche from McKinsey & Company, a management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella was a research scientist with Isis Pharmaceuticals. Stella received her B.S. in Biophysics from Peking University; her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University.
Chika Yoshinaga, MD – Vice President Asia, Sofinnova Partners
Chika Yoshinaga, MD, joined Sofinnova Partners in 2007. Over her four years as Deputy General Manager at NIF SMBC Ventures, Chika invested in five life sciences companies, four based in Europe and one in the United States. Three have completed initial public offerings: Acorda Therapeutics (NASDAQ: ACOR), BioXell (SWX: BXLN), and Innate Pharma (EURONEXT: IPH). Prior to joining the venture capital industry, Chika worked as a System Engineer in the Information System Division of the Health and Science Research Institute in Yokohama, Japan. She was also a physician intern and practiced medicine at WuaTong Hospital in Shanghai, China. Chika earned an M.S. in Bio-Engineering from Yokohama National University in Japan, as well as an M.D. in Clinical Medicine from Shanghai Medical University in China.
Albert Yu, PhD – Chairman & CEO, Hai Kang Life Corporation Ltd.
Dr. Yu is a renowned neuroscientist and bio-entrepreneur. Educated in North America, Professor Yu is the Vice-Director of the Neuroscience Research Institute, Professor of the Department of Neurobiology and also a Professor at the Infectious Disease Center at Peking University. His broad cross-cultural experience base and active involvement in both the academic and business environment has led to the strategic vision behind the success of the HK Life team. Also, with a global network and an expanding base of established contacts in China, Prof. Yu has been an important facilitator of dialogue regarding the development of biotechnology in Asia. After receiving his BSc, MSc and PhD from the University of Saskatchewan, Canada, Prof. Yu moved to the University of California at San Francisco and subsequently spent four years at Stanford University and was honored with the status of Visiting Associate Professor. Upon returning to Hong Kong, he joined the Hong Kong University of Science and Technology as a faculty member. Prof. Yu has also spent time as a guest professor at the Shanghai Jiao Tong University, visiting professor at The First Military Medical University and visiting investigator at the Chinese Academy of Sciences. Over his academic and research career, Prof. Yu has published 3 books and over 200 peer-reviewed scientific articles and conference papers. He is also the co-inventor of numerous technologies with 17 patents granted and others pending.
Tony Y. Zhang, PhD – Managing Director and Site Head, Lilly Global R&D, China
Dr. Tony Zhang is managing director and site head for Eli Lilly Global R&D, China, with responsibilities including the development of R&D strategies, establishment and management of research collaborations, and licensing activities for molecular assets and research technologies in the greater China area. Tony received his BS (1982) from Shandong University, and PhD (1989) from Purdue as a CGP fellow. He joined Eli Lilly’s Product R&D Division in 1992, and has led multi-disciplined teams engaged in the development of molecules for infectious and metabolic diseases, CNS disorders, and oncology. He is recognized as a premier molecule builder, and has patented, published, and lectured extensively in synthetic chemistry and pharmaceutical process development. He is an editorial advisory board member for the journal Organic Process R&D, and a recipient of Chairman’s Ovation award, the highest recognition within Lilly for his leadership and contribution to R&D productivity.
James Zhu, PhD, JD, MBA – Partner, Perkins Coie LLP
James J. Zhu of Perkins Coie LLP is the managing partner of the firm’s Beijing Office. James represents pharmaceutical companies like AstraZeneca, for its newly established R&D Center in China and intellectual property strategy, as well as world renowned venture capital firm Kleiner Perkins Caufield & Byers, for its investment in technology originated from China. James also helps Chinese companies license technologies originated from US companies or universities. Educated first at Fudan University in Shanghai, then earning a PhD in biology from California Institute of Technology as well as law and business degrees from Columbia University, James helps international companies protect their global IP rights and expand research capacity in the rapidly evolving but challenging IP environment in China. James has gained the reputation as the go-to source for IP and biotechnology research issues for the Sino-American life sciences industry and is very active in organizations such as the BayHelix Group, a nonprofit, invitation-only organization of leaders in the Sino-American life sciences and healthcare community, where he serves as the Chairman of the Board. James has also served as a Delegation Committee member in BIO since 2004 as a conduit between the Chinese delegation and BIO.